Our Products
Committed to engineering a healthier future
Diabetic Foot Infection
Chronic ulcers are a significant medical problem, and the incidence of these wounds is to increase as the population ages.
Approximately 28% of patients with infected diabetic foot ulcers (DFU) require amputations.
The technology use in our product consists in an innovative bacteriophage cocktail with a broad host range, composed by 5 different phage's, developed for the treatment of diabetic foot infections, specifically target the bacteria's Staphylococcus aureus, Pseudomonas aeruginosa and Acinetobacter baumannii.
The product provides an effective anti-infective treatment for chronic wound infections and contributes to antibiotic stewardship by decreasing the use of systemic antibiotics.
Granted with the Fast Track Designation by the FDA for the treatment of diabetic foot ulcers infected, our product is presently in a Phase IIb clinical trial of its development, and it is planned to be available in the market in 2025.
Respiratory Infection
The tecnology envolves a bacteriophage cocktail aims to provide a hospital-based add-on therapy to the standard of care given by inhalation.
Our treatment-oriented assessment of the underlying nosocomial infection will be performed after cross-checking of the medical data, and results of the complementary diagnostic procedures.
Spinal Cord Injury
The discovery is a binding receptor which will activate the sensory nerve leads to an inhibition of proinflammatory neuropeptide release that may provide a nerve recovery.
After the acute phase, other pathophysiological and neuroprotection mechanisms will take over induced through our product due to the anti-inflammatory properties.
During the pre-clinical stages, the product has demonstrated a clinically meaningful and statistically significant results in overall clinical parameters. Currently, product is in a Phase II clinical trial.
Diabetic Retinophaty
The tecnology consists in a single domain antibodies with high expression. With a small molecular weight has the affinity to conventional antibodie but a higher solubility, which exerts unique advantages for the recognition and binding of functional, versatile and specific target (12) all stages with diabetic retinopathy.
This finding will lead to the development of a medicine in the form of eye drops to be administrated topically. Currently, is at a discovery phase of its development plan.
Neuropathic Pain
The product is indicated for the preventive treatment of migraine in adult patients that are unresponsive to other pharmacological treatments and/ or suffer from episodic, or chronic migraine.
The product acts through a deep nasal cavity deposition associated with Breath Powered delivery enables the potential for medications to be delivered more broadly. Currently, is at a Discovery Phase.
Pipeline
